TIDMVAL
RNS Number : 0820M
ValiRx PLC
19 January 2021
19 January 2021
("ValiRx", the "Company" or the "Group")
Patent Status Update
Notification of allowance of VAL201 for the treatment of
metastatic cancer
and four other patents granted
London, UK - ValiRx plc ("ValiRx", AIM:VAL), a clinical stage
drug development company, announces that its patent portfolio
continued to build in 2020, with four patents granted during the
last 12 months (see table below).
Additionally, in January 2021, the European Patent Office
notified the Company of its intention to grant a patent which
extends patent cover for VAL201 into metastatic cancer. These
statements of protection are similar to those granted by the US
patent office announced in November 2019 and creates a broad
coverage of use of the peptide in an important area of
oncology.
The patents granted during 2020 and the notice received by the
European Patent Office in relation to VAL201 can be found
below:
Project Patent Family Patent Granted Date Granted/allowance Impact
VAL201 WO/2008/113770 JP6689430 April 2020 A new patent linked
Use of the to the previously
peptide against granted Japanese patents
cancer to strengthen the
portfolio
----------------- ---------------- ----------------------- --------------------------------
WO/2014/177868 EP number April 2021 Extends protection
Use of the to be assigned for the use of VAL201
peptide against into metastatic cancer
metastases
----------------- ---------------- ----------------------- --------------------------------
VAL301 WO/2013/064830 EP2773427 January 2021 This includes the
Use of the use in the treatment
peptide against of endometriosis,
non-cancerous as well as other non-cancerous
proliferative conditions hormone-driven
conditions conditions (including
hyperplasia)
----------------- ---------------- ----------------------- --------------------------------
VAL401 WO/2014/049071 CN104797271 March 2020 The first Chinese
patent granted for
VAL401, granted claims
include the composition
of the formulation
and use in the treatment
of cancerous and non-cancerous
disease linked to
the mechanism of action
----------------- ---------------- ----------------------- --------------------------------
JP6734346 August 2020 Covers the use of
VAL401 in the treatment
of lung cancer
----------------- ---------------- ----------------------- --------------------------------
The full patent portfolio for each project can be found on the
project pages of the Company's website:
https://www.valirx.com/our-pipeline
Dr Suzy Dilly, Chief Executive Officer commented: "It is
important for ValiRx to continue to build value in our product
portfolio by protecting intellectual property. The patenting
process involves rigorous scrutiny of the proposal, testing for
novelty and utility before a patent is allowed to be granted.
Granted patents provide protection of the intellectual value of our
research and provide further evidence to potential partners of the
value of our products.
"I am very pleased that we have continued to extend protection
across our three core products through 2020 and into January of
this year. This is an important component of value creation in the
Company and a high priority for the Board."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014. The Directors of the
Company take responsibility for this announcement.
Ends
For further information please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469
Duncan Vasey / Lucy Williams / Eran Zucker 0930
Optimum Strategic Communications Tel: +44 (0) 20 8148
Supriya Mathur/ Shabnam Bashir 3040
valirx@optimumcomms.com
About ValiRx plc
ValiRx accelerates the development of treatments in oncology and
women's health to improve patient lives. We provide the scientific,
financial and commercial framework towards enabling rapid
translation of innovative science into clinical development.
With our extensive and proven experience in research and drug
development, we select and incubate promising novel drug candidates
and guide them through an optimised process of development, from
pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and
commercial domains, with the aim of achieving a more streamlined,
less costly, drug development process. We work closely with our
selected collaborators and leverage the combined expertise required
for science to advance.
Lead candidates from our portfolio are out-licensed or partnered
with investors through ValiRx subsidiary companies for further
clinical development and commercialisation.
https://www.valirx.com/
About VAL201
VAL201 is a short peptide being studied as a potential treatment
for prostate cancer. The peptide structure is inspired by the
naturally occurring androgen receptor and is designed to intercept
and prevent the binding of the androgen receptor to SRC kinase - an
enzyme implicated in cancerous cell growth pathways. By preventing
the androgen-mediated activation of SRC kinase, VAL201 can
potentially prevent cancerous cell proliferation (or growth)
without interfering with other functions of either the androgen
receptor or SRC kinase. This precision method, mimicking a natural
process, proposes a high specificity of cancer treatment with a
lower side effect profile. VAL201 was licensed from CRT (part of
CRUK) and developed through preclinical development into this
clinical trial in patients with advanced prostate cancer. The study
was held at University College Hospital (UCLH), London.
About Prostate Cancer
Around 48,500 men are diagnosed with prostate cancer in the UK
each year [1] . In men, it is the most common cancer in the UK.
Prostate cancer is most common in older men. On average each year
35 out of 100 (35%) of new cases are in men aged 75 and over.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
Factors that could cause actual results to differ materially
from those in the forward-looking statements include risks relating
to unanticipated costs, liabilities or delays; failure or delays in
research and development programs; the safety and efficacy of the
Company's product candidates and the likelihood of clinical data to
be positive and of such product candidates to be approved by the
applicable regulatory authorities; unanticipated changes relating
to competitive factors in the Company's industry; risks relating to
the Company's capitalisation, resources and ownership structure,
the availability of sufficient resources for company operations and
to conduct or continue planned clinical development programs; the
outcome of any legal proceedings; risks related to the ability to
correctly estimate operating expenses; risks related to the ability
to project future cash utilisation and reserves needed for
contingent future liabilities and business operations; risks
related to the changes in market prices of the Company's ordinary
shares; the Company's ability to hire and retain key personnel;
changes in law or regulations affecting the Company; international,
national or local economic, social or political conditions that
could adversely affect the Company and its business; conditions in
the credit markets; risks associated with assumptions the Company
makes in connection with its critical accounting estimates and
other judgments.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDBPMFTMTIBBTB
(END) Dow Jones Newswires
January 19, 2021 02:00 ET (07:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Valirx (LSE:VAL)
Historical Stock Chart
From Mar 2023 to Mar 2024